A SNAKE VENOM DISINTEGRIN WITH POTENT ANTITUMOR AND ANTIANGIOGENIC ACTIVITY

References

• Bayless K. J., Salazar R., Davis G. E. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the avb3 and a5b1 integrins. Am. J. Pathol. 2000; 156: 1673–1683, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Boehm T., Folkman J., Browder T., O’Reilly M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Clark R. A., Cheresh D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994a; 264: 569–571, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994b; 79: 1157–1164, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Stromblad S., Klemke R., Visscher D., Sarkar F. H., Cheresh D. A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 1995; 96: 1815–1822, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brooks P. C. Role of integrins in angiogenesis. Europ. J. Cancer 1996; 32: 2423–2429, [CROSSREF]
   Google Scholar
• Brooks P. C., Klemke R. L., Schon S., Lewis J. M., Schwartz M. A., Cheresh D. A. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J. Clin. Invest. 1997; 99: 1390–1398, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brown J. M., Giaccia A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58: 1408–1416, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• DeClerck Y. A., Yean T. D., Chan D., Shimoda H., Langley K. E. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 1991; 51: 2151–2157, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Dvorak H., Nagy J., Dvorak J., Dvorak A. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 1988; 133: 95–109, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dvorak H. F. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog. Clin. Biol. Res. 1990; 354A: 317–330, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biology 1992; 3: 65–71
   PubMedGoogle Scholar
• Folkman J. Tumor Angiogenesis. Cancer Medicine, R. R. Weichselbaum. Williams & Wilkins, Baltimore 1997; 1: 181–204
   Google Scholar
• Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A., Cheresh D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500–1502, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Fujii G. Liposomal amphotericin B(AmBisome): realization of the drug delivery concept. Surfactant Science: Vessicles. Marcel Dekker, New York 1996; 491
   Google Scholar
• Fujii G., Chang J. E., Coley T., Steere B. The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 1997; 36: 4959–4968, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–992, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gasparini G., Weidner N., Maluta S., Pozza F., Boracchi P., Mezzetti M., Testolin A., Bevilacqua P., Harris A. L. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. Intl. J. Cancer 1993; 55: 739–744
   PubMed Web of Science ®Google Scholar
• Gately S., Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 2001; 7: 427–436, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Giancotti F. G., Mainiero F. Integrin-mediated adhesion and signaling in tumorgenesis. Biochim. Biophys. Acta 1994; 1198: 47–64, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Golubkov V., Hawes D., Markland F. S., Jr. Angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. Angiogenesis, 2004
   Google Scholar
• Hashizume H., Baluk P., Morikawa S., McLean J. W., Thurston G., Roberge S., Jain R. K., McDonald D. M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000; 156: 1363–1380, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hobbs S. K., Monsky W. L., Yuan F., Roberts W. G., Griffith L., Torchilin V. P., Jain R. K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci 1998; 95: 4607–4612, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Huang T. F., Yeh C. H., Wu W. B. Viper venom components affecting angiogenesis. Haemostasis 2001; 31: 192–206, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Hunter W. M., Greenwood F. C. The preparation of 131I-labeled human growth hormone of high specific activity. Nature 1962; 194: 495–503, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jain R. K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 2002; 29(Supp)3–9, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Kang I. C., Lee Y. D., Kim D. S. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res 1999; 59: 3754–3760, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kim S., Bell K., Mousa S. A., Varner J. A. Regulation of angiogenesis in vivo by ligation of integrin a5b1 with the central cell-binding domain of fibronectin. Am. J. Path. 2000; 156: 1345–1362, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kojima N., Ueno N., Takano M., Yabushita H., Noguchi M., Ishihara M., Yagi K. Effect of adriamycin entrapped by sulfatide-containing liposomes on ovarian tumor-bearing nude mice. Biotech. Applied Biochem. 1986; 8: 471–478
   Google Scholar
• Laemmli U. K. Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4. Nature 1970; 277: 680–685
   Web of Science ®Google Scholar
• Langer R. Drug Delivery and Targeting. Nature 1998; 392(Supp)5–10, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Markland F. S., Zhou Q. Snake venom disintegrin: an effective inhibitor of breast cancer growth and dissemination. Am. Chem. Soc. Symposium Series #745 2000; p. 262–282
   Google Scholar
• McLane M. A., Vijay-Kumar S., Marcinkiewicz C., Calvete J. J., Niewiarowski S. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS Lett 1996; 391: 139–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Meerovitch K., Bergeron F., Leblond L., Grouix B., Poirier C., Bubenik M., Chan L., Gourdeau H., Bowlin T., Attardo G. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul. Pharmacol 2003; 40: 77–89, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moiseeva N., Swenson S. D., Markland F. S., Jr, Bau R. Purification, crystallization and preliminary X-ray analysis of the disintegrin contortrostatin from Agkistrodon contortrix contortrix snake venom. Acta. Crystallogr. D. Biol. Crystallogr. 2002; 58: 2122–2124, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Muggia F. M. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997; 54(Supp)22–29, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Muggia F. M. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr. Oncol. Rep. 2001; 3: 156–162, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Muggia F. M., Hainsworth J. D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F. A., Morrow C. P., Paradiso L. J., Liang L. J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncology 1997; 15: 987–993, [CSA]
   PubMed Web of Science ®Google Scholar
• O’Byrne K. J., Thomas A. L., Sharma R. A., DeCatris M., Shields F., Beare S., Steward W. P. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br. J. Cancer 2002; 87: 15–20, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O’Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O’Reilly M. S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Medicine 1996; 2: 689–692, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Osborne C. K., Hobbs K., Clark G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985; 45: 584–590, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Oshikawa K., Terada S. Ussuristatin 2, a novel KGD-bearing disintegrin from Agkistrodon ussuriensis venom. J. Biochem. 1999; 125: 31–35, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pileri S. A., Roncador G., Ceccarelli C., Piccioli M., Briskomatis A., Sabattini E., Ascani S., Santini D., Piccaluga P. P., Leone O., Damiani S., Ercolessi C., Sandri F., Pieri F., Leoncini L., Falini B. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J. Pathol. 1997; 183: 116–123, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Price J. E., Polyzos A., Zhang R. D., Daniels L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990; 50: 717–721, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ritter M. R., Markland F. S. Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin. Toxicon. 2001; 39: 283–289, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ritter M. R., Zhou Q., Markland F. S. Contortrostatin, a snake venom disintegrin, induces alphavbeta3- mediated tyrosine phosphorylation of CAS and FAK in tumor cells. J. Cell Biochem. 2000; 79: 28–37, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Specialization of tumor vasculature. Nature Rev. Cancer 2002; 2: 83–90, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Russo D., Piccaluga P. P., Michieli M., Michelutti T., Visani G., Gugliotta L., Bonini A., Pierri I., Gobbi M., Tiribelli M., Fanin R., Piccolrovazzi S., Baccarani M. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann. Hematol. 2002; 81: 462–466, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sampedro F., Partika J., Santalo P., Molins-Pujol A. M., Bonal J., Perez-Soler R. Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report. J. Microencapsulation 1994; 11: 309–318, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shapiro C. L., Ervin T., Welles L., Azarnia N., Keating J., Hayes D. F. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J. Clin. Oncol. 1999; 17: 1435–1441, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sheu J. R., Yen M. H., Kan Y. C., Hung W. C., Chang P. T., Luk H. N. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. Biochim. Biophys. Acta. 1997; 1336: 445–454, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76–85, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Winer E. P. Liposomal anthracyclines for breast cancer. Semin. Oncol. 2001; 28(Supp)32–40, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Stoeltzing O., Liu W., Reinmuth N., Fan F., Parry G. C., Parikh A. A., McCarty M. F., Bucana C. D., Mazar A. P., Ellis L. M. Inhibition of integrin alpha5beta1 function with a small peptide (ATN- 161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 2003; 104: 496–503, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha vbeta 3 and alpha 5beta 1 integrins. Proc. Natl. Acad. Sci. (USA) 2003; 100: 4766–4771, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Swenson S., Costa F., Minea R., Sherwin R. P., Ernst W., Fujii G., Yang D., Markland F. S., Jr. Intravenous liposonal delivery of the snake disintegrin contortrostatin limits breast cancer progression. Mol. Cancer Ther. 2004; 3: 499–511, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Trikha M., Rote W. E., Manley P. J., Lucchesi B. R., Markland F. S. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb. Res. 1994a; 73: 39–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Trikha M., Flores M., Markland F. S. Disintegrins inhibit mammary carcinoma binding to extracellular matrix proteins. FASEB J 1994b; 8: A873
   Google Scholar
• Trikha M., De Clerck Y. A., Markland F. S. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res. 1994c; 54: 4993–4998, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Varner J. A., Cheresh D. A. Integrins and cancer. Curr. Opin. Cell Biol. 1996; 8: 724–730, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Woodle M. C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids 1993; 64: 249–262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yamada T., Kidera A. Tailoring echistatin to possess higher affinity for integrin alpha(IIb)beta(3). FEBS Lett. 1996; 387: 11–15, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Yeh C. H., Peng H. C., Huang T. F. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood 1998; 92: 3268–3276, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yuan F., Leunig M., Huang S. K., Berk D. A., Papahadjopoulos D., Jain R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352–3356, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Zhou Q., Ritter M., Markland F. S. Contortrostatin, a snake venom protein, which is an inhibitor of breast cancer progression. Mol. Biol. Cell 1996; 7(Supp)425a
   Google Scholar
• Zhou Q., Nakada M. T., Arnold C., Markland F. S. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis 1999; 3: 259–269, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Zhou Q., Hu P., Ritter M. R., Swenson S. D., Argounova S., Epstein A. L., Markland F. S. Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom. Arch. Biochem. Biophys 2000a; 375: 278–288, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou Q., Sherwin R. P., Parrish C., Richters V., Groshen S. G., Tsao-Wei D., Markland F. S. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res. Treat. 2000b; 61: 249–260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou Q., Nakada M. T., Brooks P. C., Swenson S. D., Ritter M. R., Argounova S., Arnold C., Markland F. S. Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. Biochem. Biophys. Res. Comm. 2000c; 267: 350–355, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou Q., Shieh K. Y., Markland F. S. Contortrostatin (CN), a dimeric disintegrin inhibits invasion of ovarian cancer by blocking integrin avb5. Proc. Am. Assoc. Cancer Res. 2000d; 41: 800
   Google Scholar